Clinical trials: sponsored by RenJi Hospital
Acute Myocardial Infarction, Heart Failure
The Benefits of Wearable AI in Post-Discharge Management of AMI Patients
Myocardial infarction (MI) remains a major threat to human health. Although interventional treatment techniques have advanced rapidly, many patients still experience major adverse cardiovascular events (MACE) and require hospital…
- Trial name
- NCT07288229
- Testing
- Optimized Integrated Management Based on AI-Guided Wearable Data
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Femoropopliteal Disease
Evaluation of the Clinical Outcomes of the Embolic Protection System in Preventing Distal Embolism During Femoropopliteal Debulking Procedures
Patients with femoropopliteal arterial lesions requiring debulking procedures. The objective of this study is Evaluation of the clinical outcomes of the Embolic Protection System for preventing distal embolism during…
- Trial name
- NCT07282301
- Testing
- Embolic Protection System
- Where
- China
- Volunteers
- 150 people
- Sponsor
- RenJi Hospital
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma.
- Trial name
- NEOBLAST (NCT06091124)
- Testing
- Adebrelimab, Etoposide, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- RenJi Hospital
Liver Transplantation, Tranexamic Acid
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is…
- Conditions
- Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)
- Trial name
- ESTA (NCT07157631)
- Testing
- tranexamic acid, 0.9 % saline
- Where
- China
- Volunteers
- 1,546 people
- Sponsor
- RenJi Hospital
Liver Transplantation, Renal Insufficiency, Chronic
Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment
Investigators will conduct this single-center, prospective cohort study to explore the prevalence and risk factors of renal function progression in post-liver transplantation patients with renal impairment after renal biospy and…
- Trial name
- NCT05326399
- Testing
- renal biospy
- Where
- 2 sites in China
- Volunteers
- 369 people
- Sponsor
- RenJi Hospital
Gastroesophageal Reflux Disease
Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a common chronic digestive system disorder with a high prevalence and a notably increasing trend.
- Trial name
- NCT06945237
- Testing
- Flupentixol-Melitracen + Lansoprazole
- Where
- China
- Volunteers
- 164 people
- Sponsor
- RenJi Hospital
Breast Cancer Invasive
Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2…
- Trial name
- CORINNE-PI (NCT05910398)
- Testing
- pyrotinib
- Where
- China
- Volunteers
- 488 people
- Sponsor
- RenJi Hospital
Somatization Disorder
Assessment of Somatic Symptom in Chinese Community-Dwelling People
With the rapid aging and worsening psychological problems worldwide, the special focus on somatic symptom and other psychological diseases of the older population is needed.
- Trial name
- NCT04815863
- Testing
- Assessment of somatic symptom disorder with SSS-CN, Assessment of depressive symptoms disorder with PHQ-9, Assessment of anxiety disorder with GAD-7
- Where
- 2 sites in China
- Volunteers
- 9,110 people
- Sponsor
- RenJi Hospital
Sarcopenia, Metabolic Diseases
Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)
This study aims to establish an ambispective cohort platform centered on the pathological axis of "sarcopenia-metabolic disorders-aging progression", integrating multimodal data including demographic characteristics, lifestyle…
- Conditions
- Sarcopenia, Metabolic Diseases, All-cause Mortality, Aging
- Trial name
- NCT07205510
- Testing
- nothing
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Intracranial Non-saccular Aneurysms
Safety and Efficacy of the Flow Diverter in the Treatment of Intracranial Non-saccular Aneurysm
Using data obtained from the treatment of intracranial non-saccular aneurysms with flow diverter, evaluate the effecy and safety of blood flow diverter for the endovascular treatment of intracranial non-saccular aneurysms.
- Trial name
- SAEFD (NCT07205302)
- Testing
- flow diverter
- Volunteers
- 168 people
- Sponsor
- RenJi Hospital
Epidural Hematoma, Brain Herniation
Prospective Randomized Evaluation of Decompressive Ipsilateral Craniectomy for Traumatic Acute Epidural Hematoma
Although craniotomy provides a more complete evacuation of the acute epidural hematoma, there are insufficient data to support specific surgical treatment method.
- Conditions
- Epidural Hematoma, Brain Herniation, Decompressive Craniectomy, Craniotomy
- Trial name
- PREDICT-AEDH (NCT04261673)
- Testing
- Decompressive Craniectomy, Craniotomy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- RenJi Hospital
Postpartum Hemorrhage, Systemic Autoimmune Diseases
Risk Factors for Postpartum Hemorrhage
Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women.
- Trial name
- NCT06730919
- Testing
- Estimated Blood Loss after cesarean delivery within 24 h
- Where
- 5 sites in China
- Volunteers
- 1,000 people
- Sponsor
- RenJi Hospital
Somatization Disorder
Assessment of SSD in Outpatients Using SSS-CN
About 70-80% of patients with somatic symptom disorder (SSD) visit the general medical hospital instead of psychiatric or other mental health settings.
- Trial name
- NCT03513185
- Testing
- Deanxit, SSRI or SRNI
- Where
- China
- Volunteers
- 1,863 people
- Sponsor
- RenJi Hospital
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
This study is A prospective，single arm, multicenter clinical study of BTLA monoclonal antibody JS004 (B/T lymphocyte attenuator factor monoclonal antibody) in combination with toripalimab in patients with unresectable or advanced…
- Trial name
- NCT06730932
- Testing
- JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- RenJi Hospital
Alpha-1 Antitrypsin Deficiency (AATD)
Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD)…
- Trial name
- AATD (NCT07193615)
- Testing
- YOLT-202
- Where
- China
- Volunteers
- 18 people
- Sponsor
- RenJi Hospital
Breast Cancer
Disitamab Vedotin (RC48-ADC) in Breast Cancer
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
- Trial name
- NCT05851677
- Testing
- Disitamab vedotin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- RenJi Hospital
Breast Cancer Female
Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
This is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
- Trial name
- NeoATP (NCT04126525)
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 53 people
- Sponsor
- RenJi Hospital
Locally Advanced Breast Cancer
Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
This is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant…
- Trial name
- ATP (NCT04254263)
- Testing
- pyrotinib
- Where
- China
- Volunteers
- 316 people
- Sponsor
- RenJi Hospital